Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The spike receptor-binding domain (RBD) is a critical structural domain within the SARS-CoV-2 spike glycoprotein that mediates initial viral attachment and entry into host cells[2][4]. Located within the S1 subunit of the trimeric spike protein, the RBD specifically recognizes and binds to the human angiotensin-converting enzyme 2 (ACE2) receptor on target cell surfaces[1][3][4]. Upon ACE2 binding, the RBD undergoes dynamic conformational changes characterized by transitions between "up" (receptor-accessible) and "down" (receptor-inaccessible) conformations, as well as localized structural rearrangements involving secondary structures such as α-helices, β-strands, and κ-helices[1][5][6]. The RBD has emerged as a primary therapeutic target for COVID-19 due to its essential role in viral tropism and its high immunogenicity[8]. Structural studies have revealed that the RBD's binding interface with ACE2 is stabilized by hydrogen bonds, salt bridges, and van der Waals interactions, with conformational changes at a distant hinge region facilitating viral membrane fusion[1]. The RBD is particularly attractive for vaccine development because it is more structurally homogeneous and yields higher expression levels than full-length spike ectodomain[8]. Neutralizing antibodies targeting the RBD can effectively block viral entry, and structure-based drug design efforts have identified potential inhibitors targeting the RBD and nearby polybasic cleavage sites[1][3]. These characteristics make the RBD a high-priority target for therapeutic intervention and vaccine development strategies against SARS-CoV-2 and related coronaviruses[1][2].
ACE2 receptor antagonism (blocking viral attachment); Neutralizing antibody binding; Conformational change inhibition (preventing receptor-induced structural transitions); Polybasic cleavage site targeting (indirect mechanism)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spike receptor-binding domain, SARS-CoV-2 (RBD (spike RBD or S RBD)).